California's highest court to consider whether drugmakers have 'duty to innovate'

A decision could change product liability law if it effectively required drugmakers to spend more to develop and quickly commercialize alternative products, sometimes called a "duty to innovate." The case ⁠was brought by about 24,000 HIV patients who took Gilead drugs made with tenofovir disoproxil fumarate, or TDF.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.